CTLA4 and rheumatoid arthritis: Therefore, the blocking or decrease in CD80/CD86 on the surface of the B cells and subsequent suppression of B cell-mediated T cell activation by CTLA-4-Ig may contribute to the alleviation of disease activity in RA patients.